Dual-Target SARS-CoV-2

STAR Complete

Test Benefits

The LumiraDx Dual-Target SARS-CoV-2 STAR Complete multiplex assay is intended for the detection and differentiation of nucleic acid from two distinct genes from the SARS-CoV-2 genome in nasopharyngeal or anterior nasal swab from individuals suspected of COVID-19.

  • Reliable and robust performance when compared to traditional RT-PCR tests.
  • Direct amplification within 20 minutes drives lab’s efficiency and productivity.
  • Two distinct genes to meet regions regulatory compliance.
  • Based on in silico analysis we confirm detection of all known circulating variants including Omicron, Omicron B.2 and Delta.

Test Workflows

Dual-Target SARS-CoV-2 STAR Complete - Test Workflows


Dual-Target SARS-CoV-2 STAR Complete - Performance

Not all products are available in all countries and regions. Please check with your local LumiraDx sales representative or distributor for availability in specific markets.


Supporting healthier lives, for individuals, communities and wider society.

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.

Be Informed